Time filter

Source Type

Zheng L.,Chongqing Medical University | Huang X.,Chongqing Medical University | Liang P.,Chongqing Medical University | Wen Y.,Chongqing the Third Peoples Hospital | And 5 more authors.
Hepato-Gastroenterology | Year: 2010

Background/Aims: The aim of this study was to investigate the relationship between a new tumor-relative protein (BC047440) expression and clinic pathological parameters of hepatocellular carcinoma (HCC), and to evaluate the prognostic value of BC047440 for HCC patients. Methods: Following the prokaryotic expression and polyclonal antibodies generation of BC047440, two methods, including western blot and immunohistochemical staining were employed to detect BC047440 expression in 68 HCC specimens. The correlation between BC047440 expression and clinicopathologic outcome, and prognostic value of BC047440 for HCC patients were analyzed. Results: The polyclonal antibodies could effectively recognize endogenous BC047440 in HCC tissues. Western blot and immunohistochemical staining revealed that the expression of BC047440 protein was higher in HCCs than that in adjacent tissues and normal liver tissues. Statistical analysis showed that there was a good correlation between BC047440 expression and tumor size and invasion of HCC. HCC patients with BC047440-positive expression showed a significantly poor prognosis than those with BC047440-negative expression. Conclusions: BC047440 has a regulatory function in progress of HCC and it may become a helpful indicator in handling HCC treatment and judging invasion. © H.G.E. Update Medical Publishing S.A. Source

Yang J.,Peoples Hospital of Sichuan Province | Shen Y.,University of Sichuan | Liu B.,Chengdu Army General Hospital | Tong Y.,University of Sichuan
Lung Cancer | Year: 2011

Purpose: To investigate whether methylation of BRMS1 is associated with clinical outcomes in patients with NSCLC. Methods: Methylation status of BRMS1 was examined in 325 NSCLC patients who were treated with surgery. We analyzed associations between the methylation of BRMS1 genes separately and available epidemiologic and clinical information including smoking status, gender, age, and histological type, or the stage of the tumor. Results: In the cohort of 325 NSCLC cases, 152 samples were identified as methylated (46.77%). Promoter methylation of BRMS1 was present only in 6 specimens (8.42%) in adjacent non-cancerous tissues (P=2.257×10 -14). Patient smoking history had a positive correlation with methylation rate of BRMS1 (OR=2.508, 95%CI(1.516, 4.151)). Compared with unmethylated group, methylated group showed the lower level of BRMS1 mRNA (P=0.013). And patients with a high level of BRMS1 mRNA expression had significantly better overall survival than those with low expression (P=0.002). Multivariate Cox proportional hazard regression analysis also showed that promoter methylation of BRMS1 was significantly unfavorable prognostic factors (hazard ratio, 1.912; 95% CI, and 1.341-2.726). Conclusions: These results provide clinical evidence to support the notion that BRMS1 is a NSCLC metastasis suppressor gene. Measuring methylation status of BRMS1 promotor is a useful marker for identifying NSCLC patients with worse disease-free survival. © 2011 Elsevier Ireland Ltd. Source

Li T.,University of Sichuan | Zhu D.,University of Sichuan | Zhou R.,University of Sichuan | Wu W.,Chengdu Army General Hospital | And 2 more authors.
International Journal of Sports Medicine | Year: 2012

The purpose of this study was to investigate whether hemoglobin-based oxygen carrier (HBOC) could protect the heart from intense exercise-induced myocardial dysfunction. Adult male Sprague-Dawley rats were subjected to 5-h intense prolonged running on treadmill with or without HBOC pre-treatment. Immediately after exercise, the heart rate (HR) and oxygen delivery capacity of the blood were measured. After 1 h of rest, echocardiography was performed to assess the post-exercise cardiac function. Then all the hearts were isolated and perfused using the Langendorff model for 1 h. Our results proved that pronged exercise caused significant LV dysfunction, while HBOC pre-treatment attenuated such a damage, as evidenced by the increased oxygen delivery, cardiac fractional shortening (FS), rate-pressure product (RPP), dp/dt and coronary flow rate (CF) and decreased myocardial necrosis. The releases of cardiac enzymes, including creatine kinase-MB (CK-MB) and cardiac troponin-I (cTnI) were markedly reduced. No significant difference of cardiac infarct size was observed among groups. In addition, HBOC significantly elevated superoxide dismutase (SOD) activity and decreased hydrogen peroxide (H formation, which indicated the exercise-induced cardiac oxidative damage was inhibited. In conclusion, HBOC pre-treatment showed a promising cardioprotective effect on prolonged exercise-induced cardiac dysfunction, which was probably associated with its ability to decrease myocardium oxidative stress. Source

Zhao Z.,Chongqing Medical University | Fu X.,Chinese Institute of Basic Medical Sciences | Zhang G.,Chongqing Medical University | Li Y.,Chengdu Army General Hospital | And 2 more authors.
Journal of Cellular Biochemistry | Year: 2013

The aim of this study was to elucidate the influence of receptor activity modifying protein 1 (RAMP1) overexpression on the expression and distribution of calcitonin receptor-like receptor (CRLR) in MG-63 cells. Our research also focused on whether RAMP1 overexpression enhanced the promoting effect of exogenous CGRP on osteogenic differentiation in MG-63 cells. We first constructed a eukaryotic expression vector containing human RAMP1 and stably transfected it into MG-63 cells. Real-time PCR and Western blotting were used to determine the expression levels of RAMP1 and CRLR mRNA and protein, respectively. Immunofluorescence analysis was employed to compare the distribution of CRLR in transfected cells. After treatment with CGRP, the extent of osteogenic differentiation was evaluated by simultaneous monitoring of alkaline phosphatase activity, the expression patterns of osteoblastic markers and mineralisation staining. We found that RAMP1 was more highly expressed in the transfected group compared with the control groups (P<0.01). The CRLR expression was significantly higher than that in the control groups (P < 0.05). In addition, after 7 days of CGRP treatment to induce osteogenic differentiation, the expression of collagen I mRNA was markedly increased in the transfected group (P < 0.05). The transfected group exhibited more granular precipitation in the cytoplasm with alkaline phosphatase staining after 7 and 14 days of differentiation. When stained with Alizarin Red, cells overexpressing RAMP1 were darker and formed many mineralised nodules with clear boundaries and calcium deposition typical of mineralised bone matrix structures at 28 days post-induction of differentiation. The CGRP-induced ALP activity in the RAMP1 overexpression group was significantly higher 3, 6 and 9 days after induction than that in the two control groups (P < 0.05). RAMP1 overexpression promotes CRLR expression, localisation on the cell membrane and enhanced CGRP-mediated differentiation of MG-63 cells. This study contributes to a better understanding of the molecular mechanisms governing CGRP-induced MG-63 differentiation. © 2012 Wiley Periodicals, Inc. Source

Yang J.,CAS Chengdu Institute of Biology | Yang J.,Peoples Hospital of Sichuan Province | Lan H.,Sichuan Academy of Medical science and Sichuan Provincial Peoples Hospital | Huang X.,Sichuan Academy of Medical science and Sichuan Provincial Peoples Hospital | And 2 more authors.
PLoS ONE | Year: 2012

Background: It is controversial whether microRNA-126 is a tumor suppressive or oncogenic miRNA. More experiments are needed to determine whether microRNA-126 is associated with non-small cell lung cancer risk and prognosis. Methods: Over-expression of microRNA-126 was performed to evaluate the cell invasion and tumor growth in non-small cell lung cancer (NSCLC) cell lines and nude mouse xenograft model. Gain-of-function experiments and luciferase assays were performed to reveal the relationship between microRNA-126 and PI3K-Akt signal pathway in A549 cells. We analyzed the associations of the microRNA-126 expression between genetic variants within microRNA-126 and clinical information including smoking status, sex, age, and histological type and the tumor stage. Results: Over-expression of microRNA-126 in NSCLC cell lines decreased cell proliferation in vitro and tumor growth in the nude mouse xenograft model. And microRNA-126 repressed the activity of PI3K-Akt pathway by targeting binding sites in the 3′-untranslated region of PI3KR2 mRNA. The expression level of microRNA-126 was decreased in NSCLC lines and tumor tissues. The patients with low microRNA-126 expression had significantly poorer survival time than those with high microRNA-126 expression (means for survival time (month): 24.392±1.055 vs. 29.282±1.140, P = 0.005). However, there was no significant difference in the genotype and allele frequencies of the microRNA-126 variant (G>A, rs4636297) between cases and controls (P = 0.366). In addition, there was no association between SNP rs4636297 and survival time in NSCLC patients (P = 0.992). And microRNA-126 expression had no significant difference among the three genotype groups (P = 0.972). Conclusions: Our data indicate that microRNA-126 is a tumor-suppressor gene in NSCLC and low microRNA-126 expression is a unfavorable prognostic factor in NSCLC patients. However, the regulatory mechanism of microRNA-126 remains to be elucidated in different normal and malignant tissues. Therefore, further research is needed to explore the tumor suppressive functions of microRNA-126 in NSCLC. © 2012 Yang et al. Source

Discover hidden collaborations